Ingredion to Acquire Tate & Lyle for $5 Billion, Forming Global Specialty Ingredients Powerhouse

Ingredion has unveiled plans to acquire Tate & Lyle in a recommended all-cash transaction valued at approximately £3.7 billion, equivalent to $5 billion. This strategic move is designed to establish a leading global provider of specialty ingredient solutions that emphasize healthier, tastier, and more sustainable food products.

The acquisition unites two companies with complementary expertise in areas including texturants, sugar reduction, mouthfeel, sweetening, fortification, and recipe development. Ingredion stated that the combination will strengthen its specialty ingredients platform and enhance its capacity to address shifting consumer preferences for nutritious, affordable, and high-quality food and beverages.

Geographically, the merger will integrate supply networks across the Americas, Europe, the Middle East and Africa, and Asia Pacific. This expanded footprint is expected to enable faster and more cost-effective delivery of ingredient solutions to customers on a global scale.

The transaction will also broaden formulation capabilities and accelerate innovation by combining the intellectual property, technology, and scientific expertise of both organizations.

Under the terms of the deal, Tate & Lyle shareholders will receive 595 pence per share, representing a premium of approximately 59% over the company’s closing share price on May 13, 2026. Ingredion anticipates generating annual run-rate net cost synergies of around $130 million, with full realization expected by the end of 2030.

The company projects the acquisition will be accretive to adjusted earnings per share in the first year following completion.

To finance the acquisition, Ingredion plans to utilize a combination of cash resources, new debt financing, and a committed bridge financing facility. Post-completion, the company expects net leverage to be approximately three times net debt-to-adjusted EBITDA, with plans to reduce leverage to about 2.5 times within 18 months.

The transaction is expected to close in the second half of 2027, contingent upon shareholder approvals, court sanction in the United Kingdom, and regulatory clearances.